LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Drug Manufacturers industry. Companies recently under review include Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen. Get all of our free research reports by signing up at:
http://www.activewallst.com/register/
On Wednesday, February 15, 2017, the Toronto Exchange Composite Index was up 0.37%, finishing the day at 15,844.95. The TSX Venture Composite Index, on the other hand, closed at 838.14, up 0.34%.
Additionally, the Healthcare index was up by 3.22%, ending the session at 77.28.
Active Wall St. has initiated research reports on the following equities: Nuvo Pharmaceuticals Inc. (TSX: NRI), Acerus Pharmaceuticals Corporation (TSX: ASP), and Avivagen Inc. (TSXV: VIV). Register with us now for your free membership and research reports at:
http://www.activewallst.com/register/
Nuvo Pharmaceuticals Inc.
On Wednesday, shares in Mississauga, Canada-based Nuvo Pharmaceuticals Inc. recorded a trading volume of 26,248 shares, which was higher than their three months' average volume of 11,539 shares. The stock ended the day 1.60% lower at $5.54. Nuvo Pharma's stock has advanced 1.47% in the last one month and 12.80% in the previous one year. The Company's shares are trading above its 50-day moving average. The stock's 200-day moving average of $6.31 is above its 50-day moving average of $5.51. Shares of the Company, which operates as a life sciences company, are trading at PE ratio of 1,108.00. See our research report on NRI.TO at:
http://www.activewallst.com/register/
Acerus Pharmaceuticals Corp.
Mississauga, Canada headquartered Acerus Pharmaceuticals Corp.'s stock finished Wednesday's session flat at $0.13 with a total volume of 462,169 shares traded. Over the last one month and the previous three months, Acerus Pharma's shares have rallied 6,971.43% and 7,515.38%, respectively. Furthermore, the stock has rallied 2,202.33% in the past one year. The Company's shares are trading below its 50-day and 200-day moving averages. Acerus Pharma' 50-day moving average of $1.29 is above its 200-day moving average of $0.44. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women's hormone replacement therapy, and female sexual dysfunction in Canada, are trading at a PE ratio of 9.29. The complimentary research report on ASP.TO at:
http://www.activewallst.com/register/
Avivagen Inc.
Ottawa, Canada headquartered Avivagen Inc.'s stock closed the day 4.55% lower at $0.10. The stock recorded a trading volume of 510,000 shares, which was above its three months' average volume of 372,163 shares. Shares of the company, which develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $0.15 is greater than its 50-day moving average of $0.12. Get free access to your research report on VIV.V at:
http://www.activewallst.com/register/
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active Wall Street